RCKT
Rocket Pharmaceuticals
$3.25
+$0.06 (+1.88%)Jul 27, 2026
Key metrics
The numbers that frame RCKT today
- Market cap
- $354.88M
- P/E (TTM)
- -1.7
- EV / FCF
- -1.8
- ROIC
- -94.9%
- Div yield
- 0%
- Debt / equity
- 0.1
- 52wk Low
- $2.53
- 52wk High
- $5.45
Growth
Revenue and earnings trend for RCKT
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about RCKT
Is Rocket Pharmaceuticals a good buy?
No. Rocket Pharmaceuticals has poor quality and weak momentum. Both signals point to a weaker setup. Growth looks poor. That could put pressure on the long-term business case. We think Rocket Pharmaceuticals is selling at a very high price.
What is the market capitalization of RCKT?
Rocket Pharmaceuticals's market capitalization is $354.88M.
What is the P/E ratio for RCKT stock?
Rocket Pharmaceuticals's current P/E ratio is -1.7.
What is the 52-week high for RCKT stock?
The 52-week high for Rocket Pharmaceuticals is $5.45. The current close of $3.25 is 40.4% below that high.
What is the 52-week low for RCKT stock?
The 52-week low for Rocket Pharmaceuticals is $2.53. The current close of $3.25 is 28.5% above that low.
Does RCKT stock pay dividends?
Rocket Pharmaceuticals does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for RCKT?
Rocket Pharmaceuticals's Debt / Equity ratio is 0.1.